Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …

Background Epidermal growth factor receptor (EGFR) mutation-induced drug resistance has
caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However …

The epidermal growth factor receptor (EGFR) targeted therapy has been established as a
routine strategy for treating non-small cell lung cancer (NSCLC). However, the gatekeeper …

EGFR mutation-induced drug resistance has become a major threat to the treatment of non-
small-cell lung carcinoma. Essentially, the resistance mechanism involves modifications of …

Next generation sequencing (NGS)-based tumor profiling identified an overwhelming
number of uncharacterized somatic mutations, also known as variants of unknown …

Epidermal growth factor receptor (EGFR) is an intensively focused target for anti-tumor
compounds used in non-small cell lung cancer (NSCLC) therapy. Compared to the classical …

Gefitinib and erlotinib are potent EGFR tyrosine kinase inhibitors (potentially) useful for the
treatment of non-small-cell lung cancer (NSCLC). Clinical responses, however, in NSCLC …

Introduction Epidermal growth factor receptor (EGFR) 19del and L858R mutation are known
as “common mutations” in non-small cell lung cancer (NSCLC) and predict sensitivities to …

Objectives Human non-small cell lung cancer (NSCLC) that harbors activating mutations in
epidermal growth factor receptor (EGFR) initially responds to treatment with EGFR tyrosine …

EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung
cancer (NSCLC). EGFR inhibitors have been FDA‐approved for NSCLC and have shown …